Aptose Biosciences Inc. (NASDAQ:APTO) Q2 2022 Earnings Conference Call August 2, 2022 5:00 PM ET
Company Participants
Susan Pietropaolo - Managing Director
William Rice - Chairman, President and CEO
Fletcher Payne - SVP and Chief Financial Officer
Rafael Bejar - SVP and Chief Medical Officer
Conference Call Participants
Matthew Biegler - Oppenheimer
Li Watsek - Cantor Fitzgerald
Edward Tenthoff - Piper Sandler
Soumit Roy - Jones Trading
John Newman - Canaccord Genuity
Operator
Good day, and thank you for standing by. Welcome to the Aptose Biosciences Inc. Reports Result for the Second Quarter 2022.
At this time, all participants are in a listening-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator instructions] Please be advised that today's conference is being recorded and I will now like to hand the conference over to Ms. Susan Pietropaolo. Ms. Pietropaolo, please go ahead.
Susan Pietropaolo
Thank you, Chris. Good afternoon and welcome to the Aptose Biosciences conference call to discuss financial and operational results for the second quarter ended June 30, 2022. Earlier today, Aptose issued a press release relating to these financial results. The news release, as well as related SCC filings are accessible on Aptose's website. Joining me on today's call are Dr. Dr. William G. Rice, Chairman, President and CEO and Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer and Mr. Fletcher Payne, Senior Vice President and Chief Financial Officer.
Before we proceed, I would like to remind everyone that certain statements made during this call will include forward-looking statements within the meaning of US and Canadian securities laws. Forward-looking statements reflect Aptose's current expectations regarding future events, but are not guarantees of performance and it is possible that actual results and performance could differ materially from these stated expectations. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance and achievement to differ materially from those expressed.
To learn more about these risks and uncertainties, please read the risk factors set forth in Aptose's most recent annual report on Form 10-K and SEC and SEDAR filings. All forward-looking statements made during this call speak only as of the date they are made. Aptose undertakes no obligation to revise or update the statements to reflect events or circumstances after the date of this call, except as required by law.
I will now turn the call over to Dr. Rice, Chairman, President and CEO of Aptose Biosciences. Dr. Rice?